TTI-622
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for TTI-622, covering 2025-11-04 to 2026-04-22. Get the full timeline:
Most recent: Clinical Trial Update: TTI-622 in Combination With Pembrolizumab for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma [Phase 2]